Egypt - English - EDA (Egyptian Drug Authority)

astra zeneca sweden - coated tablet

Egypt - English - EDA (Egyptian Drug Authority)

astra zeneca sweden - coated tablet

Israel - English - Ministry of Health

astra zeneca (israel) ltd - budesonide micronized - nasal spray - budesonide micronized 0.64 mg/ml - budesonide - budesonide - seasonal and perennial allergic rhinitis, and vasomotor rhinitis. preventively against nasal polyps after polypectomy. symptomatic treatment in nasal polyposis.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - exenatide - powder and solvent for suspension for injection - exenatide 2 mg - exenatide - exenatide - bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control

Israel - English - Ministry of Health

astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 200 mcg/dose - budesonide - budesonide - bronchial asthma.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 100 mcg/dose - budesonide - budesonide - bronchial asthma.

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - esomeprazole - injection, powder, for solution - 40 mg - esomeprazole 40 mg

European Union - English - myHealthbox

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/850 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets

European Union - English - myHealthbox

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/1,000 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m plus) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, astrazeneca goserelin shrinks the lesions and reduces the symptoms, including pain. astrazeneca goserelin also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. endometrial thinning: use as an endometrial thinning agent prior to endometrial ablation. assisted reproduction: pituitary down regulation in preparation for controlled ovarian superstimulation.